Nothing Special   »   [go: up one dir, main page]

NO20083446L - Fenyl-piperazinderivater som serotonin-reopptaksinhibitorer - Google Patents

Fenyl-piperazinderivater som serotonin-reopptaksinhibitorer

Info

Publication number
NO20083446L
NO20083446L NO20083446A NO20083446A NO20083446L NO 20083446 L NO20083446 L NO 20083446L NO 20083446 A NO20083446 A NO 20083446A NO 20083446 A NO20083446 A NO 20083446A NO 20083446 L NO20083446 L NO 20083446L
Authority
NO
Norway
Prior art keywords
alk
independently selected
phenyl
serotonin reuptake
reuptake inhibitors
Prior art date
Application number
NO20083446A
Other languages
English (en)
Other versions
NO332355B1 (no
Inventor
Benny Bang-Andersen
Thomas Ruhland
Ask Pueschl
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083446(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20083446L publication Critical patent/NO20083446L/no
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO332355B1 publication Critical patent/NO332355B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Forbindelse representert ved den generelle formel I hvori Y er C eller CH; X representerer S; m er 1; perO; qerO; s er O, l eller 2; den stiplede linje representerer en valgfri binding; hver R1 er uavhengig valgt fra gruppen representert ved Ci_6- alkyl, eller to R1 bundet til det sammen karbonatom kan danne et 3-6-leddet spiro-bundet cyklo-alkyl; hver R2 er uavhengig valgt fra gruppene representert ved halogen, cyano, nitro, Ci_6- alk(en/yn)yl, Ci_6- alk(en/yn)yloksy, Ci.6-alk(en/yn)ylsulfanyl, hydroksy, hydroksy-Ci_6-alk(en/yn)yl, halo- Ci_6-alk(en/yn)yl, halo- Ci_6- alk(en/yn)yloksy, C3.8-cykloalk(en)yl, C3.8-cykloalk(en)yl- Ci_6-alk(en/yn)yl, acyl, Ci.6-alk(en/yn)yloksykarbonyl, Ci.6-alk(en/yn)ylsulfonyl, eller-NRxRy; -NRxCO- d.6- alk(en/yn)yl; hver R3 er uavhengig valgt fra en gruppe representert ved Ci.6-alkyl eller d.6-alkyloksy; eller et farmasøytisk akseptabelt syreaddisjonssalt derav.
NO20083446A 2001-10-04 2008-08-06 Fenyl-piperidinderivater, deres anvendelse og farmasoytiske sammensetninger omfattende disse NO332355B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101466 2001-10-04
PCT/DK2002/000659 WO2003029232A1 (en) 2001-10-04 2002-10-02 Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Publications (2)

Publication Number Publication Date
NO20083446L true NO20083446L (no) 2004-04-21
NO332355B1 NO332355B1 (no) 2012-09-03

Family

ID=8160750

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20041628A NO326443B1 (no) 2001-10-04 2004-04-21 Fenyl-piperazindernvater som serotonin-reopptaksinhibitorer
NO20083446A NO332355B1 (no) 2001-10-04 2008-08-06 Fenyl-piperidinderivater, deres anvendelse og farmasoytiske sammensetninger omfattende disse
NO2014011C NO2014011I2 (no) 2001-10-04 2014-05-13 Vortioksetin eller et farmasøytisk akseptabelt syreaddisjonssalt dera

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20041628A NO326443B1 (no) 2001-10-04 2004-04-21 Fenyl-piperazindernvater som serotonin-reopptaksinhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2014011C NO2014011I2 (no) 2001-10-04 2014-05-13 Vortioksetin eller et farmasøytisk akseptabelt syreaddisjonssalt dera

Country Status (39)

Country Link
US (10) US7144884B2 (no)
EP (2) EP1749818B1 (no)
JP (3) JP3896116B2 (no)
KR (3) KR100783346B1 (no)
CN (1) CN1319958C (no)
AR (2) AR036659A1 (no)
AT (2) ATE386730T1 (no)
AU (2) AU2002333220C1 (no)
BE (1) BE2014C036I2 (no)
BR (3) BRPI0212733B8 (no)
CA (1) CA2462110C (no)
CO (1) CO5580746A2 (no)
CY (3) CY1107924T1 (no)
DE (2) DE60233608D1 (no)
DK (2) DK1749818T3 (no)
EA (2) EA007537B3 (no)
EG (1) EG25095A (no)
ES (2) ES2328725T3 (no)
FR (1) FR14C0033I2 (no)
HK (1) HK1072600A1 (no)
HR (1) HRP20040220A2 (no)
HU (3) HU230189B1 (no)
IL (1) IL160655A0 (no)
IS (2) IS2578B (no)
LT (1) LTC1436271I2 (no)
LU (1) LU92397I2 (no)
ME (1) ME00039B (no)
MX (1) MXPA04002959A (no)
MY (1) MY140950A (no)
NL (1) NL300652I1 (no)
NO (3) NO326443B1 (no)
NZ (1) NZ531556A (no)
PL (2) PL209253B1 (no)
PT (2) PT1749818E (no)
RS (2) RS52326B (no)
SI (1) SI1436271T1 (no)
UA (2) UA81749C2 (no)
WO (1) WO2003029232A1 (no)
ZA (1) ZA200401583B (no)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
NZ541859A (en) * 2003-04-04 2008-10-31 Lundbeck & Co As H 4-(2-Phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
EP1626720B1 (en) 2003-04-04 2008-09-03 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
NZ540891A (en) * 2003-04-04 2008-07-31 Lundbeck & Co As H 4-(2-Phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
UA81300C2 (en) * 2003-04-04 2007-12-25 Lundbeck & Co As H Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
KR20050119682A (ko) * 2003-04-04 2005-12-21 하. 룬트벡 아크티에 셀스카브 세로토닌 재흡수 억제제로서 4-(2-페닐옥시페닐)-피페리딘또는 -1,2,3,6-테트라히드로피리딘 유도체
PT1701940E (pt) 2003-12-23 2008-07-30 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-benzil-amina como ssri
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
EP1851207B1 (en) 2005-02-10 2009-07-01 Neurosearch A/S Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
JP7179035B2 (ja) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
DE602007014372D1 (de) * 2006-06-16 2011-06-16 Lundbeck & Co As H Kristalline formen von 4-ä2-(4-methylphenylsulfany norepinephrinwiederaufnahmehemmung zur behandlung neuropathischer schmerzen
EP2044020B1 (en) 2006-06-16 2011-05-04 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
PT2044043E (pt) 2006-06-16 2012-03-26 Lundbeck & Co As H 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina como um composto que combina a reabsorção de serotonina, à actividade de 5-ht3 e 5-ht1a para o tratamento de perturbação congnitiva
ES2361949T3 (es) * 2006-06-16 2011-06-24 H. Lundbeck A/S Formas cristalinas de 4-[2-(4-metilfenilsulfanil)-fenil]piperidina con inhibición de la reabsorción de serotonina y norepinefrina combinada para el tratamiento del dolor neuropático.
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
WO2008151632A1 (en) 2007-06-15 2008-12-18 H.Lundbeck A/S 4- [2- (4-methylphenylsulfanyl) phenyl] piperidine for the treatment of irritable bowel syndrome (ibs)
TWI405588B (zh) * 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
WO2009081259A1 (en) * 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
UA98698C2 (en) * 2008-03-03 2012-06-11 Х. Луннбек А/С Phenylsulfanylphenyl-piperidines and process for the preparation thereof
RU2503662C2 (ru) 2008-11-14 2014-01-10 Тереванс, Инк. Кристаллическая форма 4-[2-(2-фторфеноксиметил)фенил]пиперидинового соединения
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
PL2421534T3 (pl) * 2009-04-24 2014-12-31 H Lundbeck As Ciekłe preparaty soli 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny
ES2427628T3 (es) 2009-08-24 2013-10-31 H. Lundbeck A/S Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]piperazina
EP2493852B1 (en) * 2009-10-30 2014-04-09 Janssen Pharmaceutica NV 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators
WO2011085291A1 (en) 2010-01-11 2011-07-14 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
US8530663B2 (en) * 2010-03-22 2013-09-10 Theravance, Inc. 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
BR112012027782A2 (pt) 2010-04-30 2016-08-02 Takeda Pharmaceutical tablete entérico
MY162392A (en) * 2010-04-30 2017-06-15 Takeda Pharmaceuticals Co Enteric tablet
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
TW201212918A (en) * 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
SI3135656T1 (sl) 2011-06-20 2019-05-31 H. Lundbeck A/S Devterirani 1-piperazino-3-fenil indani za zdravljenje shizofrenije
AU2012340015B2 (en) 2011-11-14 2017-09-21 Alfasigma S.P.A. Assays for selecting a treatment regimen for a subject with depression and methods for treatment
RS58683B1 (sr) * 2012-01-03 2019-06-28 H Lundbeck As Postupak za proizvodnju 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazina
CN104797566B (zh) 2012-09-19 2017-07-07 桑多斯股份公司 沃替西汀氢溴酸盐的新结晶形式
LT2931276T (lt) 2012-12-13 2018-04-10 H. Lundbeck A/S Kompozicijos, apimančios vortioksetiną ir donepezilą
AP2015008640A0 (en) 2013-02-22 2015-08-31 Lundbeck & Co As H Vortioxetine manufacturing process
PL2981520T3 (pl) 2013-04-04 2019-09-30 Lek Pharmaceuticals D.D. Nowy sposób syntezy 1-(2-((2,4-dimetylofenylo)tio)fenylo)piperazyny
CN104109135B (zh) * 2013-04-22 2018-10-26 江苏豪森药业集团有限公司 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法
IN2013MU03121A (no) 2013-09-30 2015-07-17 Cadila Healthcare Ltd
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
SG11201604944PA (en) 2013-12-20 2016-07-28 Lundbeck & Co As H Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
EP2894154A1 (en) 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
EP3099669A1 (en) 2014-01-31 2016-12-07 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
EP2930171A1 (en) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
FR3023320B1 (fr) * 2014-07-03 2017-03-10 Ifp Energies Now Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial
CZ2014471A3 (cs) 2014-07-08 2016-01-20 Zentiva, K.S. Způsob přípravy vortioxetinu
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104292183B (zh) * 2014-09-29 2016-01-06 杨献美 一种抗抑郁药物沃替西汀的制备方法
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
EP3023417B1 (en) 2014-11-21 2017-06-28 Dipharma Francis S.r.l. Process for the preparation of an antidepressant and the intermediates thereof
CN104447622B (zh) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 氢溴酸沃替西汀β晶型的制备方法
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CZ201531A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
EP3262031A1 (en) 2015-02-25 2018-01-03 Lupin Limited Process for the preparation of vortioxetine
US20180072690A1 (en) 2015-03-26 2018-03-15 Cipla Limited Methods for Making Serotonin Reuptake Inhibitors
CN104829557B (zh) * 2015-04-23 2017-06-27 山东百诺医药股份有限公司 一种新化合物1‑[2‑（2,4‑二甲基苯基硫基）苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
MX2018000657A (es) 2015-07-17 2018-09-06 Pasteur Institut Agente estimulador del receptor 5-hidroxi triptamina 1b para usarse como un promotor de la autorrenovación y/o diferenciación de células satélite.
US20180237386A1 (en) * 2015-08-19 2018-08-23 Amneal Pharmaceuticals Company Gmbh Process For Preparation Of Vortioxetine Hydrobromide
WO2017063771A1 (en) * 2015-10-14 2017-04-20 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
US11013830B2 (en) 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
TW201806599A (zh) 2016-07-01 2018-03-01 Ｈ 朗德貝克公司 用於快速開始抗抑鬱作用之給藥方案
KR20190038840A (ko) 2016-07-15 2019-04-09 앵스띠뛰 파스퇴르 피부 및/또는 모발 복구를 위한 5-하이드록시트립타민 1b 수용체-자극제
WO2018014880A1 (zh) * 2016-07-22 2018-01-25 李勤耕 沃替西汀类似物及其用途和制备
US20190224192A1 (en) 2016-08-29 2019-07-25 Cipla Limited Stable Pharmaceutical Composition of Vortioxetine Hydrobromide
CN106349132B (zh) * 2016-08-30 2018-02-02 重庆植恩药业有限公司 沃替西汀中间体杂质及其制备方法和用途
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409728B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108409729B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
WO2018150344A1 (en) 2017-02-17 2018-08-23 Unichem Laboratories Ltd Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
WO2018154451A1 (en) * 2017-02-23 2018-08-30 Unichem Laboratories Ltd An improved process for preparation and purification of vortioxetine hydrobromide
CA3059515A1 (en) * 2017-04-25 2018-11-01 H. Lundbeck A/S Process for the manufacture of vortioxetine hbr alpha-form
EP3412661A1 (en) 2017-06-08 2018-12-12 Enantia, S.L. Cocrystals of vortioxetine hydrobromide and resorcinol
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
CN107915685A (zh) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 一种氢溴酸沃替西汀中间体的制备方法
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
ES2976985T3 (es) 2018-06-20 2024-08-14 Vio Ag Pharmaceuticals S A Enfoque de activación C-H organo-pseudocatalítica de un recipiente para la preparación de vortioxetina y producto intermedio de vortioxetina
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
CN108863986B (zh) * 2018-08-06 2020-01-21 广东东阳光药业有限公司 二氟甲基取代的苯基哌嗪衍生物及其用途
KR20220163997A (ko) 2020-04-03 2022-12-12 하. 룬드벡 아크티에셀스카브 정서적 둔마의 예방 또는 치료를 위한 1-[2-(2,4-디메틸페닐설파닐)-페닐]피페라진
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS151753B1 (no) 1971-04-13 1973-11-19
CS151755B1 (no) 1971-04-13 1973-11-19
CS151752B1 (no) 1971-04-13 1973-11-19
CS151751B1 (no) 1971-04-13 1973-11-19
YU163075A (en) * 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US4241071A (en) * 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198419A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
ES2004809A6 (es) 1987-07-29 1989-02-01 Ferrer Int Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
WO1996022977A1 (fr) * 1995-01-23 1996-08-01 Suntory Limited Ameliorant ou remede contre des symptomes provoques par des maladies ischemiques et composes utiles a cet effet
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CA2681877A1 (en) * 1997-10-31 1999-05-14 Asubio Pharma Co., Ltd. Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same
JP2002541141A (ja) 1999-04-02 2002-12-03 イコス・コーポレイション Ｉｃａｍへのｌｆａ−１結合阻害剤およびその用途
BR0012984A (pt) 1999-08-04 2002-07-16 Millennium Pharm Inc Método para tratar um estado associado com o mc4-r em um mamìfero, composto de ligação ao mc4-r, e, composição farmacêutica
IL148677A0 (en) * 1999-09-14 2002-09-12 Pharmacopeia Inc Article comprising a multi-channel dispensing head
CA2395705C (en) * 1999-12-30 2006-10-17 H. Lundbeck A/S Substituted phenyl-piperazine derivatives, their preparation and use
AU2351701A (en) 1999-12-30 2001-07-16 H. Lundbeck A/S A method for the preparation of substituted benzene derivatives
US6813639B2 (en) 2000-01-26 2004-11-02 Viaclix, Inc. Method for establishing channel-based internet access network
DE10033548C2 (de) 2000-07-11 2002-05-16 Wolfgang Papenbrock Verfahren zur Vorschau von Internetseiten
DE60205465T2 (de) * 2001-01-23 2006-04-20 Eli Lilly And Co., Indianapolis Piperazinderivate als agonisten des melanocortin-rezeptors
EP1363890A4 (en) 2001-02-07 2009-06-10 Ore Pharmaceuticals Inc MELANOCORTIN-4-RECEPTOR BINDING COMPOUNDS AND METHOD FOR THEIR APPLICATION
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
ES2280595T3 (es) * 2001-12-20 2007-09-16 H. Lundbeck A/S Derivados de ariloxifenilo y arilsulfanilfenilo.
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
EP1626720B1 (en) * 2003-04-04 2008-09-03 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
PT2044043E (pt) * 2006-06-16 2012-03-26 Lundbeck & Co As H 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina como um composto que combina a reabsorção de serotonina, à actividade de 5-ht3 e 5-ht1a para o tratamento de perturbação congnitiva

Also Published As

Publication number Publication date
AU2006215994A1 (en) 2006-10-05
MY140950A (en) 2010-02-12
BR122012023120B1 (pt) 2017-03-21
EP1436271B3 (en) 2022-04-20
PT1749818E (pt) 2009-10-06
AU2002333220B2 (en) 2008-02-07
US20160137620A1 (en) 2016-05-19
DE60233608D1 (de) 2009-10-15
SI1436271T1 (sl) 2008-06-30
JP2007051149A (ja) 2007-03-01
AU2006215994A9 (en) 2006-10-05
US9708280B2 (en) 2017-07-18
DE60225162T2 (de) 2009-02-12
CY2014022I2 (el) 2015-12-09
BR122012023120B8 (pt) 2022-01-18
JP3955613B2 (ja) 2007-08-08
MXPA04002959A (es) 2004-07-05
CY1110064T1 (el) 2015-01-14
BR122012009534B1 (pt) 2018-02-27
US20110009423A1 (en) 2011-01-13
KR20040047886A (ko) 2004-06-05
BR122012009534C8 (pt) 2021-05-25
DE60225162T3 (de) 2022-08-11
EA011096B1 (ru) 2008-12-30
EA007537B1 (ru) 2006-10-27
CO5580746A2 (es) 2005-11-30
RS52865B (en) 2013-12-31
US7144884B2 (en) 2006-12-05
JP2005505585A (ja) 2005-02-24
DK1749818T3 (da) 2009-10-12
HUS1400012I1 (hu) 2020-12-28
NO20041628L (no) 2004-04-21
ATE441631T1 (de) 2009-09-15
PL368442A1 (en) 2005-03-21
IL160655A0 (en) 2004-07-25
BR122012009534B8 (pt) 2019-01-29
BRPI0212733B8 (pt) 2021-05-25
EP1436271A1 (en) 2004-07-14
NO2014011I1 (no) 2014-05-13
US20120302553A1 (en) 2012-11-29
EP1749818A2 (en) 2007-02-07
JP3896116B2 (ja) 2007-03-22
LU92397I2 (fr) 2014-05-12
US8110567B2 (en) 2012-02-07
CN1319958C (zh) 2007-06-06
US20210276966A1 (en) 2021-09-09
RS27704A (en) 2006-10-27
BR0212733B1 (pt) 2014-05-13
HRP20040220A2 (en) 2005-02-28
HK1072600A1 (en) 2005-09-02
NO332355B1 (no) 2012-09-03
NZ531556A (en) 2005-12-23
RS52326B (en) 2012-12-31
IS7164A (is) 2004-02-26
MEP6508A (xx) 2010-02-10
UA81749C2 (uk) 2008-02-11
EP1749818A3 (en) 2008-04-02
NO326443B1 (no) 2008-12-08
AU2002333220A2 (en) 2003-04-14
IS2578B (is) 2010-02-15
US20060089368A1 (en) 2006-04-27
EA200601269A1 (ru) 2007-02-27
US7683053B2 (en) 2010-03-23
CN1561336A (zh) 2005-01-05
US20060084662A1 (en) 2006-04-20
US7138407B2 (en) 2006-11-21
NO2014011I2 (no) 2015-08-31
ATE386730T1 (de) 2008-03-15
HUP0402313A3 (en) 2010-03-29
US20140163043A1 (en) 2014-06-12
AU2006215994B2 (en) 2008-11-13
US20070060574A1 (en) 2007-03-15
AR036659A1 (es) 2004-09-22
ES2298425T7 (es) 2022-06-27
HU230189B1 (hu) 2015-09-28
HUP0402313A2 (hu) 2005-02-28
UA93857C2 (uk) 2011-03-25
LTC1436271I2 (lt) 2016-09-12
KR20070103515A (ko) 2007-10-23
CY2014022I1 (el) 2015-12-09
FR14C0033I2 (fr) 2014-11-14
US8476279B2 (en) 2013-07-02
ME00039B (me) 2010-06-10
EG25095A (en) 2011-08-17
FR14C0033I1 (no) 2014-06-13
RS20120158A3 (en) 2013-10-31
IS8806A (is) 2009-03-10
US20050014740A1 (en) 2005-01-20
DE60225162D1 (de) 2008-04-03
PL210551B1 (pl) 2012-02-29
NL300652I2 (no) 2016-01-18
AU2006215994A2 (en) 2006-10-05
JP2007031447A (ja) 2007-02-08
AR066460A2 (es) 2009-08-19
US7148238B2 (en) 2006-12-12
NL300652I1 (no) 2016-01-18
EA200400498A1 (ru) 2004-08-26
DK1436271T6 (da) 2022-06-27
CA2462110E (en) 2003-04-10
CA2462110A1 (en) 2003-04-10
BE2014C036I2 (no) 2021-11-22
BR0212733A (pt) 2004-11-16
PT1436271E (pt) 2008-04-10
AU2002333220C1 (en) 2023-10-05
US20180127389A1 (en) 2018-05-10
KR100842702B1 (ko) 2008-07-01
IS2732B (is) 2011-04-15
EP1749818B1 (en) 2009-09-02
CA2462110C (en) 2010-05-11
JP3955614B2 (ja) 2007-08-08
HU228956B1 (en) 2013-07-29
ZA200401583B (en) 2005-05-25
US10844029B2 (en) 2020-11-24
ES2328725T3 (es) 2009-11-17
KR20060118020A (ko) 2006-11-17
RS20120158A2 (en) 2012-10-31
CY1107924T1 (el) 2013-09-04
DK1436271T3 (da) 2008-06-09
ES2298425T3 (es) 2008-05-16
KR100770194B1 (ko) 2007-10-25
EP1436271B1 (en) 2008-02-20
PL209253B1 (pl) 2011-08-31
KR100783346B1 (ko) 2007-12-07
US9090575B2 (en) 2015-07-28
EA007537B3 (ru) 2015-02-27
WO2003029232A1 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
NO20083446L (no) Fenyl-piperazinderivater som serotonin-reopptaksinhibitorer
CA2318349A1 (en) Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
NO20064669L (no) Dipeptidylpeptidaseinhibitorer
HRP20020175B1 (en) N-heterocyclikc derivatives as nos inhibitors
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
MY137944A (en) Specific glucocorticoid compounds having anti-inflammatory activity
TW200724136A (en) Pharmaceutical compositions comprising PPAR modulator
BR0213025A (pt) Compostos de espiro-hidantoìna úteis como agentes antiinflamatórios
WO2002010154A3 (en) Substituted heterocyclic amides
DK1485359T3 (da) Natriumkanalblokkere
NO973635L (no) Fremgangsmåte for hemming av celle-celle adhesjon
NO20062617L (no) Anvendelse av glukosidase inhibitorer for terapi av mucovisidose
MXPA02011370A (es) Iminoazinas substituidas.
NO20081809L (no) Glukuronatsalt av en piperazinforbindelse
WO2004000762A3 (en) Propionic acid derivatives and their use as hppars activators
WO2008140099A1 (ja) テトラゾイルオキシム誘導体および植物病害防除剤
NO20054669L (no) Substituerte kinobenzoxazinanaloger
EP1634874A4 (en) imidazolidine
WO2003010142A3 (en) A process for the preparation of perindopril, its analgous compounds and salts thereof using 2,5 -dioxo-oxazolidine intermediate compounds
HRP20080243T3 (en) 4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
DK1255747T3 (da) Syntese af 3,6-dialkyl-5,6-dihydro-4-hydroxy-pyran-2-on
MXPA05013631A (es) Derivado heterociclico de metilsulfona.
EA200200108A1 (ru) Производные стрептограминов, способ их получения и композиции на их основе
PL337672A1 (en) Novel derivatives of naphtyridine or their salts
NO20040388L (no) Fremgangsmåte for fremstilling av beraprost og salter derav, samt forbindelser som er mellomprodukter i fremgangsmåten

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees